A phase II study of ALLN-177 in adolescents and adults with primary hyperoxaluria or severe forms of secondary hyperoxaluria
Latest Information Update: 14 Jan 2021
Price :
$35 *
At a glance
- Drugs Reloxaliase (Primary)
- Indications Hyperoxaluria; Primary hyperoxaluria
- Focus Therapeutic Use
- Acronyms Study 206
- Sponsors Allena Pharmaceuticals
- 08 Jan 2021 Results published in the Nephrology Dialysis Transplantation
- 18 May 2020 Results (n=14) from this study, were presented at the 115th Annual Meeting of the American Urological Association.
- 13 May 2020 According to an Allena Pharmaceuticals media release, data from this trial will be presented at the American Urological Association (AUA) Virtual Education Experience, which is being held in place of the cancelled AUA 2020 Annual Meeting.